{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T02:39:42Z","timestamp":1789785582016,"version":"4.0.1"},"reference-count":36,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1016\/j.jaci.2011.08.008","type":"journal-article","created":{"date-parts":[[2011,9,11]],"date-time":"2011-09-11T01:34:09Z","timestamp":1315704849000},"page":"1295-1302.e5","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":100,"title":["Effect of rituximab on human in\u00a0vivo antibody immune responses"],"prefix":"10.1016","volume":"128","author":[{"given":"Mark D.","family":"Pescovitz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Troy R.","family":"Torgerson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans D.","family":"Ochs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Ocheltree","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"McGee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi","family":"Krause-Steinrauf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Lachin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Canniff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Greenbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevan C.","family":"Herold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay S.","family":"Skyler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Weinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2011.08.008_bib1","first-page":"1927","article-title":"Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study","volume":"92","author":"Coiffier","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2011.08.008_bib2","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program","volume":"16","author":"McLaughlin","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaci.2011.08.008_bib3","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1023\/A:1008265313133","article-title":"Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma. The IDEC-C2B8 Study Group","volume":"9","author":"Tobinai","year":"1998","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jaci.2011.08.008_bib4","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1182\/blood.V84.8.2457.2457","article-title":"Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma","volume":"84","author":"Maloney","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2011.08.008_bib5","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1056\/NEJMoa0904452","article-title":"Rituximab, B-lymphocyte depletion, and preservation of beta-cell function","volume":"361","author":"Pescovitz","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2011.08.008_bib6","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1182\/blood.V100.6.2257","article-title":"Rituximab treatment results in impaired secondary humoral immune responsiveness","volume":"100","author":"van der Kolk","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2011.08.008_bib7","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1006\/clim.2000.4980","article-title":"Hapten-induced primary and memory humoral responses are inhibited by the infusion of anti-CD20 monoclonal antibody (IDEC-C2B8, Rituximab)","volume":"98","author":"Gonzalez-Stawinski","year":"2001","journal-title":"Clin Immunol"},{"key":"10.1016\/j.jaci.2011.08.008_bib8","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1542\/peds.47.5.927","article-title":"Primary immunodeficiencies. Report of a World Health Organization Committee","volume":"47","author":"Fudenberg","year":"1971","journal-title":"Pediatrics"},{"key":"10.1016\/j.jaci.2011.08.008_bib9","first-page":"331","article-title":"The recognition and classification of immunodeficiency diseases with bacteriophage phiChi 174","volume":"11","author":"Wedgwood","year":"1975","journal-title":"Birth Defects Orig Artic Ser"},{"key":"10.1016\/j.jaci.2011.08.008_bib10","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1172\/JCI106756","article-title":"Immunologic responses to bacteriophage phi-X 174 in immunodeficiency diseases","volume":"50","author":"Ochs","year":"1971","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaci.2011.08.008_bib11","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1182\/blood.V80.5.1163.1163","article-title":"Antibody responses to bacteriophage phi X174 in patients with adenosine deaminase deficiency","volume":"80","author":"Ochs","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2011.08.008_bib12","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1182\/blood.V92.7.2421","article-title":"Mutations of the CD40 ligand gene and its effect on CD40 ligand expression in patients with X-linked hyper IgM syndrome","volume":"92","author":"Seyama","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2011.08.008_bib13","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1182\/blood.V55.2.243.243","article-title":"The Wiskott-Aldrich syndrome: studies of lymphocytes, granulocytes, and platelets","volume":"55","author":"Ochs","year":"1980","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2011.08.008_bib14","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1097\/00007890-197312000-00015","article-title":"Studies of immunological reactivity following syngeneic or allogeneic marrow grafts in man","volume":"16","author":"Fass","year":"1973","journal-title":"Transplantation"},{"key":"10.1016\/j.jaci.2011.08.008_bib15","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/00007890-198202000-00008","article-title":"Immunological recovery in 48 patients following syngeneic marrow transplantation or hematological malignancy","volume":"33","author":"Witherspoon","year":"1982","journal-title":"Transplantation"},{"key":"10.1016\/j.jaci.2011.08.008_bib16","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/S0022-3476(85)80505-9","article-title":"Defective humoral immunity in pediatric acquired immune deficiency syndrome","volume":"107","author":"Bernstein","year":"1985","journal-title":"J Pediatr"},{"key":"10.1016\/j.jaci.2011.08.008_bib17","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/BF00915157","article-title":"Abnormal antibody responses in patients with persistent generalized lymphadenopathy","volume":"8","author":"Ochs","year":"1988","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.jaci.2011.08.008_bib18","doi-asserted-by":"crossref","first-page":"F55","DOI":"10.1097\/00002030-200003100-00004","article-title":"Progressive specific immune attrition after primary, secondary and tertiary immunizations with bacteriophage phi X174 in asymptomatic HIV-1 infected patients","volume":"14","author":"Rubinstein","year":"2000","journal-title":"AIDS"},{"key":"10.1016\/j.jaci.2011.08.008_bib19","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1086\/315739","article-title":"Evaluation of CD4+ T cell function In\u00a0vivo in HIV-infected patients as measured by bacteriophage phiX174 immunization","volume":"182","author":"Fogelman","year":"2000","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jaci.2011.08.008_bib20","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1172\/JCI5857","article-title":"CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris","volume":"103","author":"Abrams","year":"1999","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaci.2011.08.008_bib21","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.1600-6143.2003.00646.x","article-title":"Rituximab inhibits the in\u00a0vivo primary and secondary antibody response to a neoantigen, bacteriophage phiX174","volume":"5","author":"Bearden","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jaci.2011.08.008_bib22","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.2337\/dc07-2451","article-title":"Mixed-meal tolerance test versus glucagon stimulation test for the assessment of beta-cell function in therapeutic trials in type 1 diabetes","volume":"31","author":"Greenbaum","year":"2008","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jaci.2011.08.008_bib23","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/0264-410X(90)90013-C","article-title":"Safety and immunogenicity of an inactivated hepatitis A\u00a0candidate vaccine in healthy adult volunteers","volume":"8","author":"Wiedermann","year":"1990","journal-title":"Vaccine"},{"key":"10.1016\/j.jaci.2011.08.008_bib24","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1182\/blood.V84.8.2457.2457","article-title":"Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8 in patients with recurrent B-cell lymphoma","volume":"84","author":"Maloney","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2011.08.008_bib25","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3233\/HAB-2004-13301","article-title":"In\u00a0vivo human B-cell subset recovery after in\u00a0vivo depletion with rituximab, anti-human CD20 monoclonal antibody","volume":"13","author":"Sidner","year":"2004","journal-title":"Hum Antibodies"},{"key":"10.1016\/j.jaci.2011.08.008_bib26","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/art.25034","article-title":"Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial","volume":"62","author":"Bingham","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaci.2011.08.008_bib27","doi-asserted-by":"crossref","first-page":"3612","DOI":"10.1002\/art.22211","article-title":"B cell depletion therapy in systemic lupus erythematosus: effect on autoantibody and antimicrobial antibody profiles","volume":"54","author":"Cambridge","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaci.2011.08.008_bib28","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1002\/pbc.21264","article-title":"Safety, efficacy, and immune reconstitution after rituximab therapy in pediatric patients with chronic or refractory hematologic autoimmune cytopenias","volume":"50","author":"Rao","year":"2008","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.jaci.2011.08.008_bib29","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1097\/01.TP.0000112934.12622.2B","article-title":"Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics, and pharmacokinetics","volume":"77","author":"Vieira","year":"2004","journal-title":"Transplantation"},{"key":"10.1016\/j.jaci.2011.08.008_bib30","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1056\/NEJMoa066092","article-title":"Duration of humoral immunity to common viral and vaccine antigens","volume":"357","author":"Amanna","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2011.08.008_bib31","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1182\/blood-2003-04-1257","article-title":"Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma","volume":"103","author":"Horwitz","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2011.08.008_bib32","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1006\/clim.2002.5220","article-title":"Impaired primary immune response in type-1 diabetes: results from a controlled vaccination study","volume":"103","author":"Eibl","year":"2002","journal-title":"Clin Immunol"},{"key":"10.1016\/j.jaci.2011.08.008_bib33","doi-asserted-by":"crossref","first-page":"817","DOI":"10.4049\/jimmunol.174.2.817","article-title":"Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy","volume":"174","author":"Gong","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2011.08.008_bib34","doi-asserted-by":"crossref","first-page":"361","DOI":"10.4049\/jimmunol.180.1.361","article-title":"Maintenance of long-lived plasma cells and serological memory despite mature and memory B cell depletion during CD20 immunotherapy in mice","volume":"180","author":"DiLillo","year":"2008","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2011.08.008_bib35","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1126\/science.1076071","article-title":"Maintenance of serological memory by polyclonal activation of human memory B cells","volume":"298","author":"Bernasconi","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.jaci.2011.08.008_bib36","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1182\/blood-2005-08-3255","article-title":"Vaccination of human subjects expands both specific and bystander memory T cells but antibody production remains vaccine specific","volume":"107","author":"Di Genova","year":"2006","journal-title":"Blood"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674911012462?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674911012462?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T08:32:49Z","timestamp":1758789169000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674911012462"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":36,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["S0091674911012462"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2011.08.008","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2011,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of rituximab on human in\u00a0vivo antibody immune responses","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2011.08.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 American Academy of Allergy, Asthma & Immunology. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}